Market growth for bioidentical hormones is projected to reach $5.74 billion by 2031, while the FDA monitors market trends and shortages.
1 report, 1 independent
Updated Sep 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Market growth for bioidentical hormones is projected to reach $5.74 billion by 2031, while the FDA monitors market trends and shortages.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- A product was launched in the U.S. market following FDA involvement.
- FDA approval clears the path for drug market entry, driving future regulatory focus for major pharmaceutical companies.
- CStone Pharmaceuticals is seeking consensus on a global Phase III protocol for Pralsetinib, while sales increased by 500% year-over-year.
- Vanta is planning entry into the U.S. peptide market, noting that its advancing platform requires FDA-registered compounding.
- FDA clearance drives market expansion and coverage for NeurAxis, Inc.